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Melatonin is produced in the dark by the pineal gland and is a key regulator of circadian and 
seasonal rhythms. A low melatonin level was reported in individuals with autism spectrum 
disorders (ASD), but the underlying cause of this deficit was unknown. The ASMT gene, 
encoding the last enzyme of melatonin synthesis, is located on the pseudo-autosomal region 1 of 
the sex chromosomes, deleted in several individuals with ASD. In this study, we sequenced all 
ASMT exons and promoters in individuals with ASD (n=250) and compared the allelic 
frequencies with controls (n=255). Non-conservative variations of ASMT were identified, 
including a splicing mutation present in two families with ASD, but not in controls. Two 
polymorphisms located in the promoter (rs4446909 and rs5989681) were more frequent in ASD 
compared to controls (P=0.0006) and were associated with a dramatic decrease in ASMT 
transcripts in blood cell lines (P=2x10–10). Biochemical analyses performed on blood platelets 
and/or cultured cells revealed a highly significant decrease in ASMT activity (P=2x10-12) and 
melatonin level (P=3x10-11) in individuals with ASD. These results indicate that a low melatonin 
level, caused by a primary deficit in ASMT activity, is a risk factor for ASD. They also support 
ASMT as a susceptibility gene for ASD and highlight the crucial role of melatonin in human 
cognition and behavior. 
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Introduction 
Melatonin is a powerful antioxidant molecule, involved in the regulation of circadian and seasonal 
rhythms and immune function.1–4 It is released mainly by the pineal gland during the night and is 
produced by the conversion of serotonin to Nacetylserotonin by the rate-limiting enzyme AA-NAT 
(arylalkylamine N-acetyltransferase; EC 2.3.1.87), followed by the conversion of N-acetylserotonin to 
melatonin by ASMT (acetylserotonin methyltransferase; EC 2.1.1.4), also known as HIOMT 
(hydroxyindole O-methyltransferase).5 Melatonin secretion is highly heritable in humans,6 modulates 
neuronal plasticity7–9 and regulates circadian gene expression.10 It also plays a key role in 
communication behavior related to seasonal changes, such as song learning in birds.11 Abnormal 
melatonin concentrations can have a dramatic effect on human behavior, as shown in patients with 
Smith–Magenis syndrome, who have an inverted melatonin circadian rhythm and display autistic 
behavior.12 In autism spectrum disorders (ASD), low melatonin levels have been reported by three 
independent groups,13–15 but the underlying cause of this deficit and its relationship to susceptibility to 
ASD was unknown. ASD affect at least 6/1000 individuals and are characterized by impairments in 
communication skills and social interaction, as well as restricted, repetitive and stereotyped patterns of 
behavior.16–18 The genes responsible for ASD are largely unknown,19,20 but cytogenetic abnormalities 
are observed in at least 3–5% of the affected individuals.21 The PAR1 of the sex chromosomes, located 
at the tip of their short arms, has been found to be deleted in several individuals with ASD.22 Among 
the 12 PAR1 genes referenced, ASMT23 is an excellent candidate for susceptibility to ASD because it 
encodes the last enzyme in the melatonin biosynthesis pathway.24 In this study, using a combination of 
genetics and functional experiments, we report evidence showing that a low melatonin concentration 
caused by a primary deficit in ASMT activity is a risk factor for ASD. 
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Materials and Methods 
Subjects 
Families with ASD were recruited by the Paris Autism Research International Sibpair study at 
specialized clinical centers in seven countries (France, Sweden, Norway, Italy, Belgium, Austria, and 
the United States). Diagnosis was based on clinical evaluation by experienced clinicians, DSM-IV 
criteria, and the Autism Diagnostic Interview-Revised (ADI-R).25 In Sweden, the Diagnostic Interview 
for Social and Communication Disorders (DISCO-10)26 was used instead of the ADI-R in some cases. 
Patients with Asperger syndrome were evaluated with the Asperger Syndrome Diagnostic Interview.27 
Patients diagnosed with medical disorders, such as fragile X syndrome or chromosomal anomalies, 
were excluded from the study. 
For mutation screening, the study sample (n=250, 187 men and 63 women) was constituted of 250 
independent families (71 subjects from multiplex families and 179 sporadic cases) and included 233 
patients with autistic disorder and 11 with Asperger syndrome; six individuals narrowly missed the 
criteria for autistic disorder and were considered to have atypical autism (pervasive developmental 
disorder, PDD-NOS). There were 222 Caucasian, nine Black, three Asian, one Hispanic/Latin-
American family, and 15 families of mixed ethnicity. For association studies, the ASD sample 
consisted of 278 patients of Caucasian origin (201 men and 77 women) from 72 multiplex families 
and 206 sporadic cases. There were 258 patients with autism, 14 with Asperger syndrome and six with 
atypical autism. The control sample (n=255) comprised 160 French and 95 Swedish individuals. An 
additional control group of 171 individuals from North Africa was screened for rare variants because 
one proband carrying the splice-site mutation (IVS5+2T>C) and one proband with the L326F 
mutation had parents originating from this region. 
Blood and platelet biochemical analyses were performed in ASD probands (n=43; 14 female and 
29 male patients, 14.8 ± 7 years old), their parents (n=34; 18 females and 16 males: 44 ± 9 years old) 
and in controls matched for sex and age (n=75; 30 females and 45 males; 27 ± 16 years old). The ASD 
patients were initially recruited for the analysis of serotonin levels and not chosen on the basis on their 
ASMT genotype. The controls were recruited at the Department of Orthopedics of the Lariboisière and 
Robert Debré hospitals in Paris. The control group for the B lymphoblastoid cell lines (BLCL) 
biochemical analyses comprised 14 French individuals also used in the association study and 19 
healthy relatives of patients with Hirschsprung syndrome or mitochondrial diseases. The local research 
ethics boards reviewed and approved the study. Informed consent was obtained from probands (if 
possible), parents and controls. 
 
Cell culture, DNA and RNA isolation 
BLCL were established from EBV-transformed lymphocytes and grown at 37°C in RPMI-1640 
medium (Life Technologies Inc., Grand Island, NY, USA), supplemented with 10% undialyzed fetal 
calf serum, 2 mM glutamine, 2.5 mM sodium pyruvate, 100 mg/ml streptomycin and 100 IU/ml 
penicillin, under standard conditions. DNA was extracted by the phenol/chloroform method, and RNA 
was isolated using the NucleoSpin RNA II kit (Macherey-Nagel, Duren, Germany). DNA/RNA 
concentrations were determined by measuring absorbance at 260 nm on a biophotometer (Eppendorf, 
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Hamburg, Germany). Human pineal gland cDNAs were obtained from the Incyte cDNA library # 
LHS1565 (BioCat, Heidelberg, Germany). 
 
Mutation screening and genotyping 
Genotyping for the association study and mutation screening were performed by direct sequencing or 
TaqMan technology. PCR products were sequenced with the BigDye Terminator Cycle Sequencing 
Kit (V3.1, Applied Biosystems, Foster City, CA, USA). Samples were then subjected to 
electrophoresis, using an ABI PRISM genetic analyzer (Applied Biosystems). Absence of genotyping 
errors was controlled by sequencing the PCR product with the opposite primer in a subset of patients. 
For primers and PCR conditions, see Supplementary Table 1. 
 
Association and statistical analyses 
The linkage disequilibrium (LD) map for ASMT was calculated using pairwise LD (D’) between the 
13 ASMT variations in 533 individuals (278 ASD and 255 controls). The LD calculation and the case-
control study were performed with Haploview software.28 To detect population stratification bias, 
individuals with ASD and controls were screened for three single nucleotide polymorphisms (SNPs) 
(rs2289311, rs4782053, rs1921361), five ALU insertions (Ya5NBC27, Ya5NBC51, YaNBC102, 
YaNBC109, YbNBC65), and the mtDNA hypervariable region 1 (HVR1). In addition, all mothers 
from ASD patients were screened for the androgen receptor microsatellite. No significant genotype 
difference was observed for any of the markers tested (Supplementary Table 2). The transmission 
disequilibrium test (TDT) was performed using the family-based association test (FBAT)29 and 
haplotype-based association test (HBAT)30 using the empirical variance (‘-e’ option). For the TDT, 
only the four SNPs in promoter B were tested in 278 ASD families in which both parents had been 
genotyped. All SNPs were at Hardy-Weinberg equilibrium. We evaluated the distribution of the 
quantitative variables by the Kolmogorov-Smirnov test for Gaussian normality. Because the values for 
most of the samples were not normally distributed, we used the two-tailed non-parametric Mann–
Whitney U-test to compare two groups and Spearman's ρ test to evaluate the correlation between 
ASMT activity and melatonin concentration. We used SPSS version 13 for these tests. 
 
RT-PCR and quantitative RT-PCR 
Oligo(dT)-primed cDNA was prepared from 5 µg of BLCL RNA, using Superscript II (Invitrogen, 
Grand Island, NY, USA), according to the manufacturer’s instructions. The cDNAs were used directly 
in TaqMan assays, using the ABI PRISM 7500 Sequence Detection System (Applied Biosystems). 
Samples were run in duplicate or triplicate on 96-well optical PCR plates (ABgene, Surrey, UK). 
ASMT mRNA was quantified using commercially available assays. Two different assays were used, 
one covering the boundary between exon 1B and exon 2 (Hs00946625_m1), and the other covering 
the boundary between exon 8 and exon 9 (Hs00187839_m1). The two assays gave similar results and 
only the data obtained with Hs00946625_m1 are presented. Relative values of expression were 
determined for each sample, using the standard curve method (ABI user's manual), and these values 
were normalized to the threshold cycle (Ct) values of GAPDH, using the Hs99999905_m1 assay. For 
ASMT and GAPDH, the thresholds were set at 0.2 and 0.25, respectively, within the linear region of 
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the semi-logarithmic plot in all assays (data not shown). The consequence of the splice site mutation 
was investigated by sequencing the abnormal transcript after cloning the RT-PCR product. 
 
Biochemical analyses 
Blood samples were collected in the morning, between 0900 and 1100 h. The procedures for collecting 
and processing blood samples were designed to prevent release reactions. The anticoagulant was 
ACD-A (1 vol to 9 vol of whole blood). For the melatonin profile of family ASD 1, blood samples 
were collected every 2 h, from 1800 h to 1600 h the following day. Overnight, blood samples were 
collected in dimly lit conditions (<20 lux). Samples were drawn from an indwelling forearm catheter 
into Becton-Dickinson plastic tubes, centrifuged and frozen at –20°C. Platelets were counted with a 
Coulter ZBI electronic counter. ASMT enzymatic activities were determined, at least in duplicate, by 
radioenzymology,31 on the platelet pellet obtained by centrifugation of the platelet-rich plasma at 800 
g for 20 min at room temperature and lysis with 100 hemolytic units of a purified SH-activated toxin 
(streptolysin O or alveolysin, generously provided by Prof. J. Alouf, Pasteur Institute, Paris). 
Melatonin content was measured in the resulting supernatant (i.e., platelet-poor plasma or plasma) by 
HPLC, with random controls by mass spectrometry.32  
 
Sleep analysis 
The three individuals from family ASD 1 were taking no medication that could interfere with 
melatonin secretion. Sleep analysis was performed by standard polysomnography (two EEG, two 
electro-oculograms, one submental electromyogram, two anterior tibialis muscle electromyograms and 
respiratory signals, Embla N7000, Flaga, Iceland), 1 week before blood was collected for the 
melatonin assay. 
 
Results 
Rare ASMT variations in ASD and ADHD 
We investigated whether variations in ASMT were associated with ASD and ADHD by directly 
sequencing all ASMT exons and the two promoters, A and B, in 250 affected individuals. Several 
ASMT variants were identified (Figure 1), including a splice-site mutation (IVS5+2T>C), four non-
synonymous variations (N17K, K81E, G306A, L326F) and two synonymous variations (N167N, 
Q205Q). Two of these variations, N17K (rs17149149) and L326F, were observed in the general 
population. N17K was found in one family with ASD from China (ASD 3) and is present in the SNP 
database at a frequency of 0.4-0.7% in the Han Chinese population. L326F was found in two ASD 
families (ASD 6 and ASD 7) and in 3 out of 426 controls (two from Sweden and one from North-
Africa). The splice-site mutation (IVS5+2T>C) was present in two ASD families (ASD 1 and ASD 2) 
(Figure 1a), but not in controls (n=426). Using BLCL RNA from the ASD 1 proband, we detected 
abnormal ASMT transcripts, encoding a putative truncated ASMT protein, lacking the methyl-
transferase domain (Figure 1a). Biochemical analysis of the IVS5+2T>C and L326F variations 
indicated that these mutations were associated with very low levels of ASMT activity and melatonin 
(Figure 2a, 2b). We could not analyze the functional consequences of the remaining mutations due to a 
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lack of blood samples or cell lines. Interestingly, the nine individuals with ASD carrying rare 
mutations were also hyperactive and several had sleep problems (see clinical description of the 
patients in Supplementary Table 3). 
 
ASMT polymorphisms in ASD and ADHD 
We investigated whether frequent polymorphisms of the ASMT gene were associated with ASD by 
studying one insertion/deletion located in promoter A and 12 SNPs with a minor allele frequency 
greater than 5%, capturing most of the haplotype diversity (Figure 3a). ASD patients (n=278) differed 
significantly from controls (n=255) in terms of the allelic frequency of two SNPs — rs4446909 
(P=0.006) and rs5989681 (P=0.007), located in promoter B (Figure 3b, Table 1 and Supplementary 
Figure 1). The H1 GGGC haplotype in promoter B was more frequent in ASD (P=0.002) than in 
controls, whereas the haplotype H3 ACGC was more frequent in controls than in ASD (P=0.005). We 
carried out a TDT using FBAT and HBAT on 278 families (Supplementary Table 4), and observed an 
overtransmission of haplotype H1 GGGC to probands (additive model P = 0.05; dominant model P = 
0.02) and overtransmission of alleles G and C of the SNPs P1BC (dominant model P = 0.02) and 
rs6644635 (dominant model P = 0.04), respectively. 
We then explored the relationship between these frequent variations of the ASMT gene and ASMT 
expression. Promoter A activity is restricted to the retina,24 whereas promoter B is active in BLCL and 
in the pineal gland. In view of the results of quantitative RT-PCR, ASMT transcript level was found to 
be significantly associated with the two SNPs linked to ASD — rs4446909 and rs5989681 (Figure 3c). 
Interestingly, the G alleles of both SNPs were more frequent in ASD patients and were associated with 
a decrease in ASMT transcript levels by a factor of 4 to 20, respectively (rs4446909 P=2x10-8 and 
rs5989681 P=2x10-10).  
 
Serotonin, ASMT activity and melatonin concentration in ASD 
We then measured the serotonin concentration, the ASMT activity and melatonin concentration in 
blood platelets from 43 ASD patients, 34 parents of ASD patients and 48 control individuals. 
Consistent with previous studies,33 the serotonin level was significantly higher in individuals with 
ASD (P=2X10-11) and their parents (P=10-8) than in controls (Figure 4a). In contrast, the ASMT 
activity levels were significantly lower in individuals with ASD (P=2x10–12) and their parents (P=10-5) 
than in controls (Figure 4b). This deficit in ASMT activity was accompanied by a lower plasma 
melatonin concentration in patients with ASD (P=3x10-11) and their parents (P=9x10-5) than in 
controls (Figure 4c). Platelet ASMT activity and plasma melatonin levels were not correlated in 
controls (Figure 4d), whereas they were strongly correlated in patients with ASD (ρ=0.83; P=10–6). 
Thus, the decreased ASMT activity in ASD patients acted as a limiting factor for the production of 
melatonin by the pineal gland. We investigated this ASMT deficiency further by analyzing BLCLs 
from 53 individuals with ASD (for 15 of whom blood samples had already been tested) and 33 new 
independent controls (Figure 4e). We found that ASD patients had lower levels of ASMT activity than 
controls (P=7x10-8), as shown previously with platelets. These results obtained with cultured cells 
replicate our previous finding and exclude possible effects of environmental factors or regulation 
acting at a higher physiological level. We found no significant correlation between the severity of the 
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deficit and clinical phenotype (IQ, language level or ADI-R scores in the three major domains of 
impairment: Reciprocal Social Interaction, Communication, and Repetitive Behaviors and Stereotyped 
Patterns) (data not shown).  
 
Melatonin cycle and sleep pattern in family ASD 1 
Finally, we investigated circadian melatonin synthesis in vivo and sleep patterns in family ASD 1, in 
which the unaffected mother and the son with ASD carr the splice-site mutation. Neither of the 
individuals carrying the ASMT mutation — the unaffected mother and the son with ASD — showed 
the normal increase in melatonin during the night (Figure 2c). They displayed modest sleep 
abnormalities, with poor sleep efficiency (proband 70% and mother 82%; controls > 85%) and a 
moderately high arousal index (22 and 17/h; controls <10/h), but had normal proportions of rapid eye 
movement sleep (26% and 24%; control range 15%-30%) and a normal amount of slow wave sleep 
(61 and 104 min; control range: 60–120 min). 
 
Discussion 
Abnormal melatonin concentration was observed in individuals with ASD by three independent 
groups using different methodological approaches.13-15 Our results confirm that low plasma melatonin 
concentration (half the mean of the control values) is a frequent trait in ASD patients, as observed in 
65% of the patients tested, a proportion very similar (63%) to that previously reported by Tordjman et 
al.15 We show for the first time that abnormal melatonin levels are also present in the unaffected 
parents of ASD patients, suggesting a genetic origin. Indeed, the melatonin deficit observed in the 
patients was associated with low ASMT activity, suggesting that variations in the ASMT gene could be 
the cause of this deficit. This hypothesis was supported by the identification of genetic variations, 
which probably contribute to the enzymatic deficit by decreasing transcript levels, or altering the 
sequence of the ASMT protein. However, other unidentified genetic or epigenetic factors are 
contributing to the ASMT deficit since non-conservative mutations were observed only in a limited 
number of patients and the genetic association with the polymorphisms located in the ASMT promoter 
does not solely contribute to the enzymatic deficiency. Furthermore, we found unaffected relatives and 
controls with ASMT mutations and/or low melatonin concentration in the blood. Therefore, low ASMT 
activity cannot be considered as a direct cause of ASD, but as a susceptibility factor for this condition 
(less than 100 pmol melatonin/109 platelets/ 30 min; odds ratio: 77; 95% confidence interval: 19 
<OR< 320). 
Individuals with ASD frequently show irregularities in the circadian sleep–wake cycle34–36 and 
some show a free-running pattern, which is suppressed by melatonin treatment.37 In view of these 
clinical observations, it was postulated that one alteration at the origin of autism may occur as the 
child is entering into the day–night cycle.38 In agreement with this hypothesis, the deficit in melatonin 
may cause abnormal sleep–wake cycle in affected individuals. Additionally, since melatonin 
influences synaptic plasticity,5,7–9,11,39,40 a deficit in this molecule may also weaken neuronal networks, 
thereby increasing the effect of other pathological processes, such as abnormal synaptogenesis.41–44 
Taken together, these findings indicate that a subgroup of individuals with ASD and low melatonin 
levels could benefit from the use of melatonin as a therapeutic compound. Melatonin treatment seems 
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to help patients with ASD to fall asleep and to sleep through the night,37,45–48 but it remains unknown if 
melatonin could have a more beneficial effect if given before 3 years of age. Further studies are 
required to determine the role of the melatonin deficit in the affected individuals, and more generally 
of circadian and seasonal rhythms, in the susceptibility to neuropsychiatric disorders. 
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Table 1 Frequencies of the polymorphisms located in ASMT 
promoter B in ASD patients and controls 
 ASD 
(n= 278) 
Controls 
(n= 255) 
SNPs   
rs4446909   
f(G) 0.77 0.70 
P value (Pc 
valuea) 
0.006 (0.10)  
OR [95% CI]b 1.5 [1.1-2]  
rs5989681   
f(G) 0.73 0.65 
P value (Pc value) 0.007 (0.12)  
OR [95% CI] 1.4 [1.1-2]  
P1BC   
f(G) 0.90 0.90 
P value 0.78  
rs6644635   
f(C) 0.65 0.63 
P value 0.66  
Haplotypes3   
H1 GGGC 
P value (Pc value) 
0.36 
0.002 (0.04) 
0.27 
H2 GGGT 
P value 
0.26 
0.54 
0.28 
H3 ACGC 
P value (Pc value) 
0.21 
0.005 (0.08) 
0.29 
H4 GGAT 
P value 
0.097 
0.78 
0.09 
H5 GCGC 
P value 
0.055 
0.88 
0.057 
Abbreviations: ASD, autism spectrum disorders; CI, confidence interval; OR, 
odds ratio; SNP, single nucleotide polymorphism. 
aPc value: Significance levels corrected for multiple comparisons using a 
step-down permutation procedure (comprising 100,000 permutations). 
bOdds ratio: major allele vs minor allele. 
cHaplotype using rs4446909, rs5989681, P1BC and rs6644635. 
Results with significance < 0.05 are indicated in bold. 
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Figure 1 Non-synonymous ASMT variations in autism spectrum disorders (ASD) families. (a) Pedigree structure 
of the families carrying the splice–site mutation IVS5+2T>C; reverse transcriptase-polymerase chain reaction 
(RT-PCR) amplifying exons 4 to 6 of the ASMT cDNA from B lymphoblastoid cell lines of the ASD 1 proband 
carrying the splice– site mutation IVS5+2T > C (lane 1 +RT, lane 2 –RT) and a control (lane 3 +RT, lane 4        
–RT). The insertion (+Ins) of 31 bp in the ASMT transcript originates from a cryptic donor splice–site 
downstream from exon 5. This insertion should lead to the additional sequence indicated in red and to a frame 
shift (characters in italics), causing premature truncation of the protein, lacking the methyl-transferase domain. 
Wt, wild-type. (b) Pedigree structure of the families carrying rare non-synonymous ASMT variations and 
conservation of the variant amino-acid in different species. Color codes in the pedigrees: autism with mild 
(orange) or severe (red) mental retardation, Asperger syndrome or high-functioning autism (yellow), attention-
deficit/ hyperactivity disorder ADHD (light blue) and depression (pink). The proband ASD 3 fulfilled diagnostic 
criteria for both high functioning autism and ADHD. The proband ASD 7 fulfilled diagnostic criteria for both 
Asperger syndrome and ADHD. The asterisk and the dot indicate the presence of the mutation and the absence 
of a DNA sample for analysis, respectively. 
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Figure 2 Impact of the ASMT mutations on enzyme activity and melatonin concentration. (a) ASMT activity, 
measured in platelets of the members of families autism spectrum disorder (ASD) 1 and ASD 6 carrying the 
splice–site IVS5+2T>C and the L326F ASMT mutations, respectively. (b) Blood melatonin concentration in the 
same individuals. (c) Nocturnal melatonin profile of family ASD 1. The proband (male, 24 years old) and his 
mother (53 years old) are heterozygous (m/+) for the splice–site mutation IVS5+2T>C. The proband’s father (55 
years old) has no ASMT mutation (+/+). Error bars represent s.d. C: controls; F: father; M: mother; P: proband. 
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Figure 3 Association studies and transcript analyses of the ASMT gene. (a) Haplotype block structure of the 
ASMT gene. The relative physical position of each single nucleotide polymorphism (SNP) is given in the upper 
diagram, and the pairwise LD (D0) between all SNPs is given below each SNP combination. (b) Plot of the 
case–control P-values (–log10) for all variations studied within ASMT. 1: E1A; 2: rs4446909; 3: rs5989681; 4: 
P1BC; 5:rs6644635; 6: rs6588802; 7: rs28675287; 8: rs6588809; 9: I6A; 10: rs7471973; 11: rs5431942; 12: 
rs4933063; 13: rs11346829. SNPs located in promoter B are included in the shaded box. P-values for the risk 
haplotype GGGC are indicated as straight lines with close (cases vs controls) or open circles (transmission 
disequilibrium test (TDT)). (c) Quantification of ASMT transcripts relative to rs4446909 and rs5989681 
genotypes (A represents the individuals with an A/A or A/G genotype; C represents the individuals with C/C or 
C/G genotype; G represents the individuals homozygous G/G). Black and white circles indicate individuals with 
autism spectrum disorders (ASD) and controls, respectively. The gray symbols indicate individuals homozygous 
A/A and C/C for rs4446909 and rs5989681, respectively. Real-time reverse transcriptase (RT)-PCR was 
performed with B lymphoblastoid cell lines from 38 ASD probands and 29 controls. Horizontal bars indicate 
medians. No statistical difference was observed between ASD and controls (Mann–Whitney U-test). 
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Figure 4 ASMT activity and melatonin concentration in patients, parents and controls. (a) Serotonin 
levels, measured in the platelets of 43 ASD patients (mean±s.d.; 1±0.6 µM), 34 parents (0.8±0.2 µM) 
and 48 controls (0.4±0.2 µM). (b) ASMT activity, measured in the platelets of 43 ASD patients 
(0.73±0.43 pmol/109 platelets/30 min), 34 parents (1.20±0.85 pmol/109 platelets/30 min) and 48 
controls (1.81±0.68 pmol/109 platelets/30 min). (c) Plasma melatonin concentration in 43 autism 
spectrum disorders (ASD) patients (73±36 pmol), 34 parents (99±46 pmol) and 48 controls (136±39 
pmol). (d) Blood melatonin concentration expressed with respect to ASMT activity in platelets. 
ASMT activity and melatonin concentration were not correlated in controls (white circles). In contrast, 
in ASD patients (black circles), and their parents (white triangles), a significant correlation was 
observed. Spearman’s rho test was used to evaluate the correlation between ASMT activity and 
melatonin concentration. (e) ASMT activity in B lymphoblastoid cell lines from 53 ASD patients 
(3.9±3.4) and 33 controls (8.3±2.4). Circles and squares indicate female and male subjects, 
respectively. Statistical significance was assessed with the Mann–Whitney U-test. 
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Supplementary Table 1. ASMT primers used in this study 
Exon Exon size (bp) 
PCR fragment size 
(bp) 
Primers 
Annealing 
(°C) 
Sequencing    
1A 78 875 ASMT1AF: GAGCGATTCTTCTGCCTCAGC 
ASMT1AR: TCTGCGCACACTCCCAGGTG 
67 
1B/C 136 
(coding 69) 
491 ASMT1BF: GAGGCAGGAGAATCGCTTGAA 
ASMT1BR: CAACAATGGAACGTGAGTGTG 
65 
 
2 175 552 ASMT2F: TGGTGCAATCTCATTTGACTCTG 
ASMT2R: GGGTTCATGCCATTCTCCTG 
58 
3 130 950 ASMT3F: CAGCTGTACAAGGCAAGAGGA 
ASMT3R: CTTTCACCTCCTCCACTGCCA 
55 
4 69 283 ASMT4F: GCCTGGGCTACAGAGCTGAAA 
ASMT4R: CTCCTGGGTTGTGCCATTTG 
55 
5 119 331 ASMT5F: CCTGTGGGGTATAGCTCCGTTC 
ASMT5R: CGCACATGTCAAAGCATCAGA 
64 
6 84 342 ASMT6F: AGCTTGCAGTGAGCGGAAATC 
ASMT6R: GCACCCATCGACTCGTCATTT 
64 
7 141 352 ASMT7F: TGGGTTGGACCCTTCATGAGT 
ASMT7R: GTGTTTCCGGGAGTGAGAGGA 
64 
8 123 338 ASMT8F: AGCCTGGAAGACCTGGGAAAG 
ASMT8R: CCTGTGGGATGATTTCAGTGC 
64 
9 279 
(coding 212) 
506 ASMT9F: GGTGCCCTGACTGTCCTCTGA 
ASMT9R: CCATCAGCGTGGTCCTCAGTA 
64 
Expression    
E 4-6  223  ASMTsplice4F: CCAGTACCTGGAGACGTTTGG 
ASMTexp6R1: TCCTTGCGATAGTTTGCTGA  
55 
All PCRs were performed with Qiagen HotStarTaq at the following temperatures: 15 min at 95°C, 
35 cycles of: 30 s at 95°C, 30 s at annealing temperature, 0.5-1 min at 72°C, followed by a final 
extension step of 10 min at 72°C. One 28 bp insertion/deletion located 194 bp upstream from exon 
1A was used for the association study. bp, base pairs. 
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Supplementary Table 2. Stratification of the ASD and control populations used for 
the case control study.  
Variations Allele ASD Control Chi2 df p value 
SNPs       
RS2289311 A 0.66 0.66 0.06 1 0.8 
RS4782053 G 0.67 0.69 0.4 1 0.5 
RS1921361 C 0.64 0.62 0.1 1 0.7 
Alu       
Ya5NBC27 Empty 0.71 0.76 3.4 1 0.07 
Ya5NBC51 Empty 0.57 0.58 0.07 1 0.8 
YaNBC102 Empty 0.64 0.64 0.1 1 0.8 
YaNBC109 Full 0.60 0.56 1.7 1 0.2 
YbNBC65 Empty 0.51 0.54 0.8 1 0.4 
Microsatellite1       
Androgen receptor Multiple alleles   15 19 0.7 
MtDNA2       
HVR1 Multiple Haplotypes   1.6 3 0.6 
1Mothers of children with ASD and affected girls were compared to control females. 2The test 
concerns the haplotype matching the control reference sequence and those containing the 
variations 16126, 16223 located in the hypervariable region 1 (HVR1) of the mtDNA. df, degrees 
of freedom. 
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Supplementary Table 3. Clinical features of patients with rare variants of the ASMT  gene 
Family 
and 
patient
Location and 
nucleotide 
change
Protein 
change
ASMT 
activity 
deficit
Inheritance Sex
Age at last 
evaluation 
(years)
Ethnic 
origin Diagnosis
Cognitive 
level Language Attention/ Hyperactivity/ Sleep Seizures Family history
ASD 1
Patient 1 IVS5+2T>C Frameshift mutation yes Maternal M 25 European autism mild MR
language delay (started 
to speak at 5y)
ADHD symptoms present until the 
age of 12 y. Abnormal sleep 
pattern, falls asleep very late, 
nocturnal awakenings.
—
The father has depression, the mother is 
healthy but she has a particular sleep 
organization, sleeping only when she’s very 
tired, at any time, otherwise sleeping few 
hours.
ASD 2
Patient 1 — — nd — M 12 North Africa autism mild MR no language delay
Hyperactivity during childhood; no 
longer present at 12 y —
Three affected children from two fathers; 
the mother and the father of the two 
younger sibs are healthy, no information 
about the father of the first child
Patient 2 IVS5+2T>C Frameshift mutation nd Paternal M 7
North 
Africa autism severe MR non verbal
Severe hyperactivity during 
childhood; still pesent at 7 y +
Patient 3 IVS5+2T>C Frameshift mutation nd Paternal M 4
North 
Africa autism severe MR non verbal Hyperactive in the evening +
ASD 3
Patient 1 exon 1B, C51A N17K nd Maternal M 9  China
autism + 
ADHD 
combined 
type
low normal first words 14 m  sentences 36 m ADHD; no sleep problems — Only child. Negative family history.
ASD 4
Patient 1 exon 2, A241G K81E nd Maternal M 8 African-American autism mild MR
first words 19 m ,  
sentences  40 m
Slept very little during the first 
years  but his sleep is now normal. 
Marked hyperactivity and difficulty 
maintaining attention 
—
Father: negative medical and psychiatric 
history; mother: depressive episode during 
first pregancy
ASD 5
Patient 1 exon 9, G917C G306A nd Maternal M 12 European autism mild MR
first words 14 m, 
sentences at 36 m, 
followed by language 
regression 
Motor hyperactivity; very active 
during night  —
The parents have no medical or psychiatric 
history.
Patient 2 exon 9, G917C G306A nd Maternal M 9 European autism severe MR
language development 
stopped at 15 m; very 
limited language at 9 y
Motor hyperactivity —
ASD 6
Patient1 exon 9, C976T L326F yes Maternal M 11 North Africa autism severe MR 
first words 18 m,  
never acquired any 
sentences
Motor hyperactivity; normal sleep. — The parents have no medical or psychiatric history
ASD 7
Patient 1 exon 9, C976T L326F nd Maternal M 6 European
Asperger + 
ADHD 
combined 
type
normal first words 24 m,  sentences 36 m ADHD, no sleep problems. —
The parents have no medical or psychiatric 
history
MR, mental retardation; nd, not determined
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Supplementary Table 4. TDT of the polymorphisms located in ASMT promoter B in 
278 families with ASD using FBAT and HBAT. 
   Additive model  Dominant model 
 freq  fam# S E(S) Var(S) Z P  fam# S E(S) Var(S) Z P 
SNPs                
rs4446909 
A 
G 
 
0.25 
0.75 
  
104 
104 
 
81 
163 
 
84 
160 
 
55 
55 
 
-0.4 
0.4 
 
0.68 
0.68 
  
104 
39 
 
66 
31 
 
68 
30 
 
35 
13 
 
-0.4 
0.2 
 
0.7 
0.8 
rs5989681 
C 
G 
 
0.3 
0.7 
  
110 
110 
 
93 
171 
 
96 
167 
 
62 
62 
 
-0.4 
0.4 
 
0.66 
0.66 
  
114 
55 
 
78 
46 
 
79 
43 
 
40 
15 
 
-0.12 
0.7 
 
0.9 
0.48 
P1BC 
A 
G 
 
0.12 
0.88 
  
67 
67 
 
38 
128 
 
45 
121 
 
29 
29 
 
-1.29 
1.29 
 
0.2 
0.2 
  
73 
12 
 
44 
13 
 
48 
10 
 
28 
1.3 
 
-0.8 
2.4 
 
0.42 
0.02 
rs6644635 
C 
T 
 
0.64 
0.36 
  
119 
119 
 
206 
104 
 
193 
117 
 
73 
73 
 
1.54 
-1.54 
 
0.12 
0.12 
  
68 
128 
 
66 
90 
 
57 
95 
 
18 
50 
 
2 
-0.7 
 
0.04 
0.51 
Haplotypes                
H1 GGGC 0.34  116 197 183 52 1.97 0.05  115 164 150 34 2.3 0.02 
H2 GGGT 0.24  105 133 137 52 -0.47 0.63  105 121 120 44 0.2 0.9 
H3 ACGC 0.23  102 114 115 50 -0.21 0.83  92 101 100 33 0.07 0.9 
H4 GGAT 0.11  63 55 57 25 -0.42 0.67  62 54 56 23 -0.3 0.7 
H5 GCGC 0.05  38 26 28 12 -0.69 0.49  38 26 28 12 -0.7 0.5 
Freq, frequency; fam#, number of informative families; S, observed transmission; E(S), expected 
transmission; Var(S) Variance of the transmission observed. P values below 0.05 are indicated in 
bold. 
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Supplementary Figure 1. Sequence and variations of promoter B of the ASMT gene. The 
SNPs used in the association analysis are indicated in pink. The two SNPs associated with low 
transcript levels are rs4446909 and rs5989681, 109 bp apart, in strong linkage disequilibrium 
(D’= 0.94). The SNP rs4446909 is located –207 bp from the transcription site, in a CCCAC box 
(yellow). Six nucleotides downstream, there is a CAAT/10 mer box (bright green) also present in 
promoter A. SNP rs5989681 is located 97 bp upstream from the transcription site (+1), in a 
putative binding site for the transcription factor NF-kappaB (orange). A putative binding site for 
AP1-TRE and a sequence homologous to that of ASMT promoter A are indicated in gray and dark 
green, respectively. A GC-rich region resembling an Sp1 site is underlined. Repeat sequences 
overlapping the transcription initiation site are shown in italics. The five variants indicated in red 
(-213 A/T, -160 C/T, -56 C/A, -45 C/T, +11 C/G) were observed in five patients, but not in 
controls (n=426). Two patients had the same combination of variations, –45 T and +11 G. 
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